Conference - Princeton, NJ, United States
The session will focus on establishing the swiftest pathway for registration of Biosimilars in USAPast experiences of FDA regarding 10-20 year biologics approvals has paved the way to entry of biosimilars – therefore, a new paradigm is emerging, not only with an emerging new class of products but also a fresh Pharma and Regulator awareness of novel recombinant therapeutic proteins including monoclonal antibodies. Development strategies of a new generation of selective biologics including Biobetters are emerging. Also, Regulators worldwide now demand a higher quality standard of biologics.
Presented By: Dr. Hoss A Dowlat, RA, VP, Global Strategy, Pharma-Bio Consulting
Organization: Biopractice (http://www.biopractice.com/bioevents/)
Website: http://www.biopractice.com/bioevents/Seminar_31714.html
Monday, 4th August, 2014 (09:00 AM - 05:00 PM)
NJHA Conference & Event Center
Princeton, NJ, United States
Contact: Gopal (marketing@biopractice.com)
Phone: 1-646-216-8860
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
